10x Genomics, Inc. TXG
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Ask Irving AI About TXG
Get to know the stock you’re researching through a simple conversation. Ask Irving about its Weiss rating, financial health, dividends, and potential risks — right from the stock page.
Get answers about this stock. Instantly.
Ask about the company’s financial health and its Weiss Safety, Reward, and Risk Ratings, with answers grounded in Weiss Ratings data.
Understand the numbers behind the rating.
Explore profits, cash flow, valuation, and dividends. Ask follow-up questions without leaving the stock page.
Put the stock’s strengths and risks in context.
Look beyond a single number. Explore rating changes and company trends to better understand the stock’s outlook.
Company Overview
10x Genomics, Inc. is a U.S.-based life sciences technology company focused on developing tools and platforms for analyzing biological systems at high resolution. The company operates primarily within the genomics, biotechnology, molecular diagnostics, and life sciences research industries. Its technologies are widely used in single-cell analysis, spatial biology, and immune profiling, supporting applications in academic research, pharmaceutical development, translational medicine, and clinical discovery. Revenue is generated primarily through sales of instruments, consumables, and software services tied to recurring research workflows.
The company’s core business is centered on integrated genomic analysis platforms, including the Chromium, Visium, and Xenium product families. These systems enable researchers to examine gene expression, chromatin accessibility, and cellular interactions with single-cell and spatial resolution. 10x Genomics has built a competitive position through proprietary microfluidics technology, high-throughput sequencing compatibility, and an ecosystem of consumables that generate recurring revenue. Founded in 2012 by Serge Saxonov, Ben Hindson, and Kevin Ness, the company expanded rapidly following the commercialization of its Chromium platform and became publicly traded on Nasdaq in 2019.
Business Operations
10x Genomics reports operations primarily through integrated genomics technology platforms that support biological discovery and translational research. Its principal business units include the Chromium Single Cell Gene Expression, Chromium Immune Profiling, Chromium Cell ATAC, Visium Spatial Gene Expression, and Xenium In Situ platforms. The company generates revenue from instrument sales, consumable reagent kits, and software associated with sequencing workflows. Consumables represent a substantial recurring revenue stream because customers repeatedly purchase reagents and assay kits tied to installed systems.
Operations are concentrated in the United States but extend internationally through direct sales teams and distribution networks across Europe and Asia-Pacific. The company controls proprietary microfluidics, molecular barcoding, imaging, and bioinformatics technologies central to its platforms. 10x Genomics has also expanded through acquisitions and partnerships, including the acquisition of ReadCoor and CartaNA, which strengthened its spatial biology capabilities and contributed to the development of the Xenium platform. The company collaborates with sequencing ecosystem participants, including compatibility integrations with Illumina sequencing systems widely used in genomic research laboratories.
Strategic Position & Investments
10x Genomics has positioned itself as a leading provider of single-cell and spatial biology technologies, with strategic emphasis on expanding multiomic analysis and high-resolution tissue imaging. Growth initiatives have focused on increasing adoption of spatial transcriptomics and in situ analysis tools, particularly through the commercialization of the Xenium platform. The company continues investing heavily in research and development to improve assay sensitivity, throughput, and software analytics capabilities for complex biological datasets.
The company has pursued acquisitions and intellectual property expansion to strengthen its technology portfolio. Acquisitions including ReadCoor and CartaNA enhanced its spatial genomics offerings, while continued investment in software and imaging systems supports broader integration across genomics workflows. 10x Genomics also maintains substantial patent holdings related to droplet microfluidics and single-cell sequencing technologies, which form a strategic barrier to entry in the market. The company operates in highly competitive sectors alongside firms involved in sequencing, molecular diagnostics, and spatial biology technologies.
Geographic Footprint
10x Genomics is headquartered in Pleasanton, California, and maintains a global commercial and operational presence across North America, Europe, and Asia-Pacific. Its products are used by academic institutions, pharmaceutical companies, biotechnology firms, hospitals, and government research organizations worldwide. The United States remains its largest market, but international markets contribute a significant share of revenue through expanding adoption of single-cell and spatial biology tools.
The company supports global operations through regional offices, distributor relationships, and localized commercial teams in countries including the United Kingdom, Germany, China, Singapore, Japan, and Australia. Its technologies are broadly deployed in biomedical research centers and translational medicine programs internationally, particularly in oncology, immunology, neuroscience, and cell therapy research applications.
Leadership & Governance
10x Genomics was co-founded by Serge Saxonov, Ben Hindson, and Kevin Ness, with Serge Saxonov continuing to play a central leadership role. The company’s leadership strategy has emphasized long-term innovation in genomics tools, investment in platform expansion, and development of integrated hardware-software ecosystems that support high-throughput biological analysis. Governance and operational oversight are shaped through executive leadership and board supervision consistent with public company reporting standards outlined in SEC filings, including annual reports and proxy disclosures.
Key executives include:
- Serge Saxonov – Co-Founder and Chief Executive Officer
- Adam Taich – Chief Financial Officer
- Benjamin J. Hindson – Co-Founder and Chief Scientific Officer
- James R. Hawkins – Senior Vice President, Operations
- Eric S. Whitaker – Chief Legal Officer and Secretary
Public disclosures indicate leadership priorities centered on expanding the installed instrument base, increasing consumables adoption, advancing spatial biology technologies, and supporting large-scale biological discovery initiatives across global research markets.